| Date | Form | Description | Docs | XBRL | Pages |
| 09/06/19 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
84 |
| 06/12/19 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
39 |
| 03/13/19 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
35 |
| 09/07/18 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
33 |
| 06/11/18 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
34 |
| 03/09/18 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
31 |
| 09/08/17 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
35 |
| 05/26/17 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
32 |
| 03/16/17 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
31 |
| 08/19/16 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
35 |
Latest News & Events
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
Read More...Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
Read More...Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Read More...